Receptor dependent multidimensional QSAR for modeling drug - Receptor interactions

Current Medicinal Chemistry

Volumn 16, Issue 25, 2009, Pages 3243-3257

  Polanski, Jaroslaw ^a  

^a UNIVERSITY OF SILESIA   (Poland)

Author keywords

3 7D QSAR; Multidimensional QSAR; Receptor based drug design; Receptor dependent QSAR

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; ENZYME INHIBITOR; ESTROGEN RECEPTOR; GLYCOGEN PHOSPHOYLASE INHIBITOR; NONSTRUCTURAL PROTEIN 5B INHIBITOR; PEPTIDOMETIC RENIN INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PORPHYRIN; PROTEINASE INHIBITOR; RENIN INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; THERMOLYSIN INHIBITOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; BINDING SITE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER MODEL; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; GENETIC ALGORITHM; HUMAN; HYDROPHOBICITY; INTERMETHOD COMPARISON; INTERNET PROTOCOL; MATHEMATICAL MODEL; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MOLECULAR SIZE; MULTIVARIATE ANALYSIS; NONHUMAN; PHARMACOPHORE; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SOLVATION; STRUCTURAL EQUATION MODELING; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS;

COMPUTER SIMULATION; DRUG DESIGN; LIGANDS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, DRUG;

EID: 70249139317     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788803286     Document Type: Review

References (128)

1. Kolb, C.; Finn, G.; Sharpless, B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew. Chem. Int. Ed., 2001, 40, 2004-2021
2. Lehn, J.M.; Eliseev, A.V. Dynamic combinatorial chemistry. Science, 2001, 291, 2331-2332
3. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature, 2004, 432, 855-861 (Pubitemid 40037141)
4. Polanski, J. In Comprehensive Chemometrics; Walczak, B., Tauler Ferré, R., Brown S., Eds.; Elsevier: Amsterdam, 2009, pp. 459-506.
5. Polanski, J.; Bak, A.; Gieleciak, R.; Magdziarz, T. Modeling robust QSAR. J. Chem. Inf. Model., 2006, 46, 2310-2318
6. Böhm, H.-J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput.-Aided Mol. Des., 1994, 8, 243-256
7. Krystek, S.; Stouch, T.; Novotny, J. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures. J. Mol. Biol., 1993, 234, 661-679 (Pubitemid 24007794)
8. Head, R.D.; Smythe, M.L.; Oprea, T.I.; Waller, C.L.; Green, S.M.; Marshall, G.R. Validate: A New Method for the Receptor-Based Prediction of Binding Affinities of Novel Ligands. J. Am. Chem. Soc., 1996, 118, 3959-3969
9. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors, Wiley-VCH: Weinheim, 2000.
10. Vedani, A.; Dobler, M.; Lill, M.A. The challenge of predicting drug toxicity in silico. Basic Clin. Pharmacol. Toxicol., 2006, 99, 195-208. (Pubitemid 44321483)
11. Lill, M.A.; Vedani, A. Multi-dimensional QSAR in drug design - Application to GPCRs and nuclear receptors. Curr. Comput.-Aided Drug. Des., 2005, 1, 307-324
12. Ermondi, G.; Caron, G. Recognition forces in ligand-protein complexes: blending information from different sources. Biochem. Pharmacol., 2006, 72, 1633-1645 (Pubitemid 44764998)
13. Polanski, J. In Chemoinformatics: From Data to Knowledge; Gasteiger, J., Ed.; Wiley-VCH: Weinheim, 2003; Vol.1, pp. 302-319.
14. Arteca, G.A. In Reviews in Computational Chemistry; Lipkowitz, L.B.; Boyd D.B., Eds.; VCH Publishers: New York, Weinheim, Cambridge, 1996; Vol 9, pp191-253.
15. Goodford, P. In Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction; Cruciani, G.; Mannhold, R.; Kubinyi, H.; Folkers, G. Eds., Wiley VCH: Weinheim 2006; pp. 3-26.
16. von Itzstein, M.; Wu, W.Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Van Phan, T.; Smythe, M.L.; White, H.F.; Oliver, S.W.; et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363, 418-423 (Pubitemid 23179386)
17. Lushington, G.H.; Guo, J.X.; Wang, J.L. Curr. Med. Chem., 2007, 14, 1863-1877
18. Cruciani, G.; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds., Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction; Wiley VCH: Weinheim 2006.
19. Lukacova, V.; Balaz, S. Multimode Ligand Binding in Receptor Site Modeling: Implementation in CoMFA. J. Chem. Inf. Comput. Sci., 2003, 43, 2093-2105.
20. Ortiz, A.R.; Pisabarro, M.T.; Gago, F.; Wade, R.C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem., 1995, 38, 2681-2691
21. Jain, A.N.; Koile, K.; Chapman, D. Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark. J. Med. Chem., 1994, 37, 2315-2327
22. Ivanciuc, O.; Ivanciuc, T.; Cabrol-Bass, D. Comparative receptor surface analysis (CoRSA) model for calcium channel antagonists. SAR QSAR Environ. Res., 2001, 12, 93-111.
23. Hofbauer, C.; Lohninger, H.; Aszódi, A. SURFCOMP: a novel graph-based approach to molecular surface comparison. J. Chem. Inf. Comput. Sci., 2004, 44, 837-847
24. http://teachme.tuwien.ac.at/surfcomp
25. Polanski J. Drug design using comparative molecular surface analysis. Expert Opin. Drug Discov., 2006, 1, 693-707.
26. Vedani, A.; Dobler, M.; Zbinden, P. Quasi-Atomistic Receptor Surface Models: A Bridge between 3-D QSAR and Receptor Modeling. J. Am. Chem. Soc., 1998, 120, 4471-4477 (Pubitemid 28261208)
27. Vedani, A.; Briem, H.; Dobler, M.; Dollinger, K.; McMasters, D. Multiple conformation and protonation-state representation in 4DQSAR: The neurokinin-1 receptor system. J. Med. Chem., 2000, 43, 4416-4427 (Pubitemid 32046866)
28. Vedani, A.; McMasters, D. R.; Dobler, M. Multi-conformational ligand representation in 4D-QSAR: Reducing the bias associated with ligand alignment. Quant. Struct.-Act. Relat., 2000, 19, 149-161 (Pubitemid 30240803)
29. Vedani, A.; Dobler, M. 5D-QSAR: The key for simulating induced fit? J. Med. Chem., 2002, 45, 2139-2149 (Pubitemid 34525794)
30. Dobler, M.; Vedani, A. User and reference manual quasar 5.2, http://www.biograf.ch.
31. Hopfinger, A.J.; Wang, S.; Tokarski, J.S.; Jin, B.; Albuquerque, M.; Madhav, P.J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119, 10509-10524 (Pubitemid 27487990)
32. Polanski, J.; Gieleciak, R.; Magdziarz, T.; Bak, A. GRID formalism for the comparative molecular surface analysis: application to the CoMFA benchmark steroids, azo dyes, and HEPT derivatives. J. Chem. Inf. Comput. Sci., 2004, 44, 1423-1435
33. Polanski, J. The receptor-like neural network for modeling corticosteroid and testosterone binding globulins. J. Chem. Inf. Comput. Sci., 1997, 37, 553-561 (Pubitemid 127603565)
34. Bak, A.; Polanski, J. Modeling robust QSAR 3: SOM-4D-QSAR with iterative variable elimination IVE-PLS: application to steroid, azo dye, and benzoic acid series. J. Chem. Inf. Model., 2007, 47, 1469-1480 (Pubitemid 47210050)
35. McInnes, C. Virtual Screening Strategies in Drug Discovery Current Opinion in Chemical Biology. Curr. Opin. Chem. Biol., 2007, 11, 494-502.
36. Zentgraf, M; Steuber, H., Koch, C.; La Motta, C.; Sartini, S.; Sotriffer, C.A.; Klebe, G. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase. Angew. Chem. Int. Ed., 2007, 46, 3575-3578 (Pubitemid 46973461)
37. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches; VCH: Weinheim, 1993.
38. Karelson, M. Molecular Descriptors in QSAR/QSPR; Wiley: New York, 2000.
39. www.talete.mi.it.
40. http://www.codessa-pro.com.
41. Wold, S.; Johansson, E.; Cocchi, M. In 3D QSAR in Drug Design, Theory, Methods, and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp. 523-550
42. http://support.sas.com/rnd/app/da/new/dapls.html
43. Esposito, E. X.; Hopfinger, A.J.; Madura, J. D. In Chemoinformatics: From Data to Knowledge; Gasteiger, J., Ed.; Wiley-VCH: Weinheim, 2003; Vol.4, pp. 1576-1599
44. Rücker, C.; Rücker, G.; Meringer, M. Y-Randomization and its variants in QSPR/QSAR. J. Chem. Inf. Model., 2007, 47, 2345-2357
45. Polanski, J.; Gieleciak, R.; Bak, A. Probability issues in molecular design. Predictive and modeling ability in 3D-QSAR schemes. Comb. Chem. High Throughput Screen., 2004, 7, 793-807. (Pubitemid 39561721)
46. Polanski, J. Self-organizing neural networks for pharmacophore mapping. Adv. Drug Deliver. Rev., 2003, 55, 1149-1162 (Pubitemid 37098281)
47. Polanski, J.; Walczak, B. The comparative molecular surface analysis (CoMSA):A novel tool for molecular design. Comput. Chem., 2000, 24, 615-625 (Pubitemid 30869471)
48. Centner, V.; Massart, D.L.; De Noord, O.E.; De Jong, S.; Vandeginste, B.M.V.; Sterna, C. Elimination of uninformative variables for multivariate calibration. Anal. Chem., 1996, 68, 3851-3858 (Pubitemid 126682543)
49. Grohmann, R.; Schindler, T. Toward robust QSPR models: Synergistic utilization of robust regression and variable elimination. J. Comput. Chem., 2008, 29, 847-860
50. Arakawa, M.; Hasegawa, K.; Funatsu, K. The Recent Trend in QSAR Modeling - Variable Selection and 3D-QSAR Methods. Curr. Comput.-Aided Drug Des., 2007, 3, 254-262 (Pubitemid 350268173)
51. Melani, F.; Gratteri, P.; Adamo, M.; Bonaccini, C. Field interaction and geometrical overlap: A new simplex and experimental design based computational procedure for superposing small ligand molecules. J. Med. Chem., 2003, 46, 1359-1371 (Pubitemid 36512700)
52. Lemmen, C.; Lengauer, T. Computational methods for the structural alignment of molecules. J. Comput. Aided Mol. Des., 2000, 14, 215-232 (Pubitemid 30175941)
53. Ho, C. M. W. In Chemoinformatics in Drug Discovery; Oprea, T., Ed.; Wiley-VCH: Weinheim, 2005, pp. 199-219.
54. Doweyko, A.M. 3D-QSAR illusions. J. Comput. Aided Mol. Des., 2004, 18, 587-596
55. Tokarski, J.S.; Hopfinger, A.J. Prediction of ligand-receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic renin inhibitors. J. Chem. Inf. Comput. Sci., 1997, 37, 792-811.
56. Romeiro, N.C.; Albuquerque, M.G.; de Alencastro, R.B.; Ravi, M.; Hopfinger, A.J. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. J. Mol. Model., 2006, 12, 855-868
57. Santos-Filho, O.A.; Mishra, R.K.; Hopfinger, A.J. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors. J. Comput. Aided Mol. Des., 2001, 15, 787-810.
58. Venkatarangan, P.; Hopfinger, A.J. Prediction of ligand-receptor binding thermodynamics by free energy force field threedimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Med. Chem., 1999, 42, 2169-2179
59. San Juan, A.A. 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. Bioorg. Med. Chem. Lett., 2008, 18, 1181-1194 (Pubitemid 351179335)
60. Patel, P.D.; Patel, M.R.; Kaushik-Basu, N.; Talele, T.T. 3D QSAR and molecular docking studies of benzimidazole derivatives as hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model., 2008, 48, 42-55. (Pubitemid 351271049)
61. Pissurlenkar, R.R.; Shaikh, M.S.; Coutinho, E.C. 3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment. J. Mol. Model., 2007, 13, 1047-1071 (Pubitemid 47308386)
62. Huang, H.; Pan, X.; Tan, N.; Zeng, G.; Ji, C. 3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II. Eur. J. Med. Chem., 2007, 42, 365-372 (Pubitemid 46349367)
63. Tuccinardi, T.; Nuti, E.; Ortore, G.; Supuran, C.T.; Rossello, A.; Martinelli, A. Analysis of human carbonic anhydrase II: docking reliability and receptor-based 3D-QSAR study. J. Chem. Inf. Model., 2007, 47, 515-525 (Pubitemid 46615953)
64. Jójárt, B.; Márki, A. Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists. J. Mol. Graph. Model., 2007, 25, 711-720 (Pubitemid 46188548)
65. Sheng, C.; Zhang, W.; Ji, H.; Zhang, M.; Song, Y.; Xu, H.; Zhu, J.; Miao, Z.; Jiang, Q.; Yao, J.; Zhou, Y.; Zhu, J.; Lü, J. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J. Med. Chem., 2006, 49, 2512-2525
66. Zhang, N.; Jiang, Y.; Zou, J.; Zhang, B.; Jin, H.; Wang, Y.; Yu, Q. 3D QSAR for GSK-3beta inhibition by indirubin analogues. Eur. J. Med. Chem., 2006, 41, 373-378
67. Xiao, J.; Guo, Z.; Guo, Y.; Chu, F.; Sun, P. Inhibitory mode of Nphenyl- 4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses. Protein Eng. Des. Sel., 2006, 19, 47-54. (Pubitemid 43162256)
68. Aparna, V.; Jeevan, J.; Ravi, M.; Desiraju, G.R.; Gopalakrishnan, B. 3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment methods. Bioorg. Med. Chem. Lett., 2006, 16, 1014-1020 (Pubitemid 43059870)
69. Iskander, M.N.; Leung, L.M.; Buley, T.; Ayad, F.; Di Iulio, J.; Tan, Y.Y.; Coupar, I.M. Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment. Eur. J. Med. Chem., 2006, 41, 16-26.
70. Zhou, Z.; Madura, J.D. CoMFA 3D-QSAR analysis of HIV-1 RT nonnucleoside inhibitors, TIBO derivatives based on docking conformation and alignment. J. Chem. Inf. Comput. Sci., 2004, 44, 2167-2178
71. Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.: Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl) carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. J. Med. Chem., 2005, 48, 213-223
72. Datar, P.A.; Coutinho, E.C. A CoMFA study of COX-2 inhibitors with receptor based alignment. J. Mol. Graph. Model., 2004, 23, 239-251
73. Xu, Y.; Liu, H.; Niu, C.; Luo, C.; Luo, X.; Shen, J.; Chen, K.; Jiang, H. Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)- butanes based on the structural modeling of human CCR5 receptor. Bioorg. Med. Chem., 2004, 12, 6193-6208 (Pubitemid 39440457)
74. Sippl, W. Development of biologically active compounds by combining 3D QSAR and structure-based design methods. J. Comput. Aided Mol. Des., 2002, 16, 825-830 (Pubitemid 36701519)
75. Mekenya, O.; Kamenska, V.; Serafimova, R.; Poellinger, L.; Brouwer, A.; Walker, J. Development and validation of an average mammalian estrogen receptor-based QSAR model. SAR QSAR Environ. Res., 2002, 13, 579-595.
76. Sippl, W. Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. Bioorg. Med. Chem., 2002, 10, 3741-3755 (Pubitemid 36164678)
77. Roh, E.J.; Kim D.; Choi, J.Y.; Lee, B.S.; Lee, C.O.; Song, C.E. Synthesis, biological activity and receptor-based 3-D QSAR study of 3′-N-substituted-3′-N-debenzoylpaclitaxel analogues. Bioorg. Med. Chem., 2002, 10, 3135-3143 (Pubitemid 34855387)
78. Sippl, W. Receptor-based 3D QSAR analysis of estrogen receptor ligands - merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods. J. Comput. Aided Mol. Des., 2000, 14, 559-572 (Pubitemid 30445059)
79. Lee, J.Y.; Doddareddy, M.R.; Cho, Y.S.; Choo, H.; Koh, H.Y.; Kang, J.H.; No, K.T.; Pae,.N., Comparative QSAR studies on peptide deformylase inhibitors. J. Mol. Model., 2007, 13, 543-558
80. Tuccinardi, T.; Ortore, G.; Rossello, A.; Supuran, C.T.; Martinelli, A. Homology modeling and receptor-based 3D-QSAR study of carbonic anhydrase IX. J. Chem. Inf. Model., 2007, 47, 2253-2262 (Pubitemid 350275090)
81. Costanzi, S.; Tikhonova, I.G.; Ohno, M.; Roh, E.J.; Joshi, B.V.; Colson, A.O.; Houston, D.; Maddileti, S.; Harden, T.K.; Jacobson, K.A. P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. J. Med. Chem., 2007, 50, 3229-3241
82. Fox, T. In: Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction, Cruciani, G.; Mannhold, R.; Kubinyi, H.; Folkers, G. Eds., Wiley VCH: Weinheim 2006; pp. 45-82.
83. Schneider, G.; Baringhaus, K-H. Molecular Design Concepts and Applications, Wiley-VCH: Weinheim, 2008.
84. Totrov, M. Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR. Chem. Biol. Drug. Des., 2008, 71, 15-27.
85. Romeiro, N.C.; Albuquerque, M.G.; de Alencastro, R.B.; Ravi, M.; Hopfinger, A.J. Construction of 4D-QSAR models for use in the design of novel p38-MAPK inhibitors. J. Comput. Aided Mol. Des., 2005, 19, 385-400.
86. Bak, A.; Polanski, J. Modeling robust QSAR 3: SOM-4D-QSAR with iterative variable elimination IVE-PLS: application to steroid, azo dye, and benzoic acid series. J. Chem. Inf. Model., 2007, 47, 1469-1480 (Pubitemid 47210050)
87. Senese, C.L.; Hopfinger, A.J. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci., 2003, 43, 2180-2193
88. Senese, C.L.; Hopfinger, A.J., Receptor-independent 4D-QSAR analysis of a set of norstatine derived inhibitors of HIV-1 protease. J. Chem. Inf. Comput. Sci., 2003, 43, 1297-1307
89. Liu, J.; Pan, D.; Tseng, Y.; Hopfinger, A.J. 4D-QSAR analysis of a series of antifungal p450 inhibitors and 3D-pharmacophore comparisons as a function of alignment. J. Chem. Inf. Comput. Sci., 2003, 43, 2170-2179
90. Pasqualoto, K.F.; Ferreira, E.I.; Santos-Filho, O.A.; Hopfinger, A.J. Rational design of new antituberculosis agents: receptorindependent four-dimensional quantitative structure-activity relationship analysis of a set of isoniazid derivatives. J. Med. Chem., 2004, 47, 3755-3764
91. Polanski, J.; Bak, A. Modeling steric and electronic effects in 3D-and 4D-QSAR schemes: predicting benzoic pK(a) values and steroid CBG binding affinities. J. Chem. Inf. Comput. Sci., 2003, 43, 2081-2092
92. Polanski, J.; Bak, A.; Gieleciak, R.; Magdziarz, T. Self-organizing neural networks for modeling robust 3D and 4D QSAR: application to dihydrofolate reductase inhibitors. Molecules, 2004, 9, 1148-1159 (Pubitemid 40145169)
93. Bak, A., Polanski, J. A 4D-QSAR study on anti-HIV HEPT analogues. Bioorg. Med. Chem., 2006, 14, 273-279 (Pubitemid 41635489)
94. Pan, D.; Tseng, Y.; Hopfinger, A.J. Quantitative structure-based design: formalism and application of receptor-dependent RD-4DQSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Comput. Sci., 2003, 43, 1591-1607
95. Pan, D.; Liu, J.; Senese, C.; Hopfinger, A.J.; Tseng, Y. Characterization of a ligand-receptor binding event using receptor-dependent four-dimensional quantitative structure-activity relationship analysis. J. Med. Chem., 2004, 47, 3075-3088 (Pubitemid 38702703)
96. Santos-Filho, O.A.; Hopfinger, A.J. Structure-based QSAR analysis of a set of 4-hydroxy-5,6-dihydropyrones as inhibitors of HIV-1 protease: an application of the receptor-dependent (RD) 4D-QSAR formalism. J. Chem. Inf. Model., 2006, 46, 345-354
97. Coats E. The CoMFA steroids as a benchmark dataset for development of 3D QSAR methods. Persp. Drug Discov. Design, 1998, 199-213. (Pubitemid 128488932)
98. Cherkasov, A.; Ban, F.; Santos-Filho, O.; Thorsteinson, N.; Fallahi, M.; Hammond, G.L. An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone- binding globulin. J. Med. Chem., 2008, 51, 2047-2056
99. Vedani, A.; Dobler, M. Multi-dimensional QSAR: Moving from three- to five- dimensional concepts. Quant. Struct.-Act. Relat., 2002, 21, 382-390
100. Vedani, A.; Dobler, M.; Lill, M.A. Combining protein modeling and 6D-QSAR - Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem., 2005, 48, 3700-3703
101. Lill, M.A.; Vedani, A. Combining 4D pharmacophore generation and multi-dimensional QSAR: Modeling ligand binding to the Bradykinin B2 receptor. J. Chem. Inf. Model., 2006, 46, 2135-2145 (Pubitemid 44625984)
102. Ducki, S.; Mackenzie, G,; Lawrence, N.J.; Snyder, J.P. Quantitative structure-activity relationship (5D-QSAR) study of combretastatin- like analogues as inhibitors of tubulin assembly. J. Med. Chem., 2005, 48, 457-465
103. http://www.biograf.ch/PDFS/Yeti.pdf
104. http://www.biograf.ch/PDFS/Raptor.pdf
105. Lill, M.A.; Dobler, M.; Vedani, A. Prediction of small-molecule binding to Cytochrome P450 3A4: Flexible docking combined with multi-dimensional QSAR. ChemMedChem., 2006, 1, 73-81. (Pubitemid 44104980)
106. Lill, M.A.; Winiger, F.; Vedani, A.; Ernst, B. Impact of induced fit on the ligand binding to the androgen receptor: A multi-dimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals. J. Med. Chem., 2005, 48, 5666-5674 (Pubitemid 41298341)
107. Vedani, A.; Zumstein, M.; Lill, M.A.; Ernst, B. Simulating α/β specificity at the thyroid receptor: Consensus scoring in multidimensional QSAR. ChemMedChem., 2007, 2, 78-87.
108. Vedani,A.; Spreafico, M.; Peristera, O.; Dobler, M., Smiesko, M. VirtualToxLab - in silico prediction of the endocrine-disrupting potential of drugs and chemicals. Chimia, 2008, 62, 322-328
109. Vedani, A.; Descloux, A.V.; Spreafico, M.; Ernst, B. Predicting the toxic potential of drugs and chemicals in silico: A model for the peroxisome proliferator-activated receptor . Toxicol. Lett. 2007, 173, 17-23. (Pubitemid 47211705)
110. Bonneau, S.; Morlière, P.; Brault, D. Dynamics of interactions of photosensitizers with lipoproteins and membrane-models: correlation with cellular incorporation and subcellular distribution. Biochem. Pharmacol., 2004, 68, 1443-1452 (Pubitemid 39179401)
111. Vernier, G.; Chenal, A.; Vitrac, H.; Barumandzadhe, R.; Montagner, C.; Forge, V. Interactions of apomyoglobin with membranes: mechanisms and effects on heme uptake. Protein Sci., 2007, 16, 391-400. (Pubitemid 46327550)
112. Sailer, R.; Strauss, W.S.; Wagner, M.; Emmert, H.; Schneckenburger, H. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines. Photochem. Photobiol. Sci., 2007, 6, 145-151 (Pubitemid 46233591)
113. Ji, Z.; Yang, G.; Vasovic, V.; Cunderlikova, B.; Suo, Z.; Nesland, J.M.; Peng, Q. Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. J. Photochem. Photobiol. B., 2006, 84, 213-220 (Pubitemid 44184915)
114. Kulkarni, A.S.; Hopfinger, A. J. Membrane-interaction QSAR analysis: application to the estimation of eye irritation by organic compounds. Pharm. Res., 1999, 16, 1245-1253
115. Kulkarni, A.; Han, Y.; Hopfinger, A.J. Predicting Caco-2 cell permeation coefficients of organic molecules using membraneinteraction QSAR analysis. J. Chem. Inf. Comput. Sci., 2002, 42, 331-342 (Pubitemid 35355308)
116. Iyer, M.; Tseng, Y.J.; Senese, C.L.; Liu, J.; Hopfinger, A.J. Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis. Mol. Pharm., 2007, 4, 218-231
117. Kulkarni, A.; Hopfinger, A.J.; Osborne, R.; Bruner, L.H.; Thompson, E.D. Prediction of eye irritation from organic chemicals using membrane-interaction QSAR analysis. Toxicol. Sci., 2001, 59, 335-362
118. Kodithala, K.; Hopfinger, A.J.; Thompson, E.D.; Robinson, M.K. Prediction of skin irritation from organic chemicals using membrane- interaction QSAR analysis. Toxicol. Sci., 2002, 66, 336-346
119. Chen, C.; Yang, J. MI-QSAR models for prediction of corneal permeability of organic compounds. Acta Pharmacol. Sin., 2006, 27, 193-204. (Pubitemid 43171158)
120. Chen, L.L.; Yao, J.; Yang, J.B.; Yang, J. Predicting MDCK cell permeation coefficients of organic molecules using membraneinteraction QSAR analysis. Acta Pharmacol. Sin., 2005, 26, 1322-1333 (Pubitemid 41607004)
121. Iyer, M.; Mishru, R.; Han, Y.; Hopfinger, A.J. Predicting blood-brain barrier partitioning of organic molecules using membrane-interaction QSAR analysis. Pharm. Res., 2002, 19, 1611-1621 (Pubitemid 35305512)
122. Santos-Filho, O.A.; Hopfinger, A.J.; Zheng, T. Characterization of skin penetration processes of organic molecules using molecular similarity and QSAR analysis. Mol. Pharm., 2004, 1, 466-476
123. Liu, J.; Li, Y.; Pan, D.; Hopfinger, A.J. Predicting permeability coefficient in ADMET evaluation by using different membranes-interaction QSAR. Int. J. Pharm., 2005, 304, 115-123.
124. Liu, J.; Yang, L. Effect of cholesterol on DMPC phospholipid membranes and QSAR model construction in membrane-interaction QSAR study through molecular dynamics simulation. Bioorg. Med. Chem., 2006, 14, 2225-2234 (Pubitemid 43254735)
125. Wade, R.C.; Henrich, S.; Wang, T. Using 3D protein structures to derive 3D-QSARs. Drug Discov. Today: Techn., 2004, 1, 2416. (Pubitemid 40197572)
126. Esposito, E.X.; Hopfinger, A.J.; Madura, J.D. In Chemoinformatics: Concepts, Methods, and Tools for Drug Discovery; Bajorath, J., Ed.; Humana Press: Tetowa, New Yersey, 2004, pp. 131-213.
127. Doweyko AM. QSAR: dead or alive? J. Comput. Aided Mol. Des., 2008, 22, 81-89
128. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2, 192-204. (Pubitemid 37361664)